|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,123.75 GBX | -1.25% |
|
+0.81% | -9.33% |
| 07-16 | MedTech facing a three-front squeeze |  |
| 07-15 | Smith+Nephew Launches Lynx Coblation Laryngeal Wand for Ent Surgeons | CI |
Business description: Smith & Nephew Plc
- orthopedic surgery (39.5%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.4%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (29.1%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.6% of net sales.
Number of employees: 16,988
Sales by Activity: Smith & Nephew Plc
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Orthopaedics | 2.16B | 2.11B | 2.21B | 2.3B | 2.44B |
Sports Medicine & ENT | 1.56B | 1.59B | 1.73B | 1.82B | 1.93B |
Advanced Wound Management (AWM) | 1.5B | 1.51B | 1.61B | 1.68B | 1.79B |
Geographical breakdown of sales: Smith & Nephew Plc
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 2.66B | 2.76B | 2.98B | 3.12B | 3.31B |
Other Established Markets (Excluding US and UK) | 1.45B | 1.32B | 1.41B | 1.48B | 1.61B |
Emerging Markets (Excluding China) | 564M | 628M | 684M | 770M | 875M |
United Kingdom | 189M | 186M | 201M | 226M | 246M |
China | 352M | 319M | 275M | 210M | 128M |
Executive Committee: Smith & Nephew Plc
| Manager | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | 54 | 31/03/2022 |
John Rogers
DFI | Director of Finance/CFO | 58 | 31/03/2024 |
| Chief Tech/Sci/R&D Officer | 59 | 31/07/2016 | |
Alison Parkes
CMP | Compliance Officer | - | 31/12/2021 |
Paul Connolly
COO | Chief Operating Officer | - | 10/10/2021 |
Composition of the Board of Directors: Smith & Nephew Plc
| Director | Title | Age | Since |
|---|---|---|---|
Marc Owen
BRD | Director/Board Member | 67 | 30/09/2017 |
| Director/Board Member | 62 | 31/10/2020 | |
John Ma
BRD | Director/Board Member | 64 | 16/02/2021 |
Jo Hallas
BRD | Director/Board Member | - | 31/01/2022 |
Deepak Nath
BRD | Director/Board Member | 54 | 31/03/2022 |
Rupert Soames
CHM | Chairman | 67 | 25/04/2023 |
Jeremy Maiden
BRD | Director/Board Member | 65 | 13/09/2023 |
John Rogers
BRD | Director/Board Member | 58 | 30/04/2024 |
Simon Lowth
BRD | Director/Board Member | 65 | 31/12/2023 |
Sybella Stanley
BRD | Director/Board Member | 65 | 31/01/2025 |
Holdings: Smith & Nephew Plc
| Name | Stocks | % | Valuation |
|---|---|---|---|
BIOVENTUS INC. 9.2% | 6,229,991 | 9.2% | 59 M $ |
Company details: Smith & Nephew Plc
Group companies: Smith & Nephew Plc
| Name | Category and Sector |
|---|---|
Plus Orthopedics Hellas SA | |
Smith & Nephew ESN Ltd. | |
Smith & Nephew Hellas SA | |
Smith & Nephew Healthcare Pvt Ltd.
 Smith & Nephew Healthcare Pvt Ltd. Medical/Nursing ServicesHealth Services Provides healthcare services |
Medical/Nursing Services
|
Smith & Nephew GBS Pvt Ltd.
 Smith & Nephew GBS Pvt Ltd. Medical DistributorsDistribution Services Manufactures and distributes orthopedic devices and instruments |
Medical Distributors
|
Medical Devices & Implants
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.25% | +0.81% | -0.49% | -6.69% | 12.85B | |
| -0.23% | -3.71% | -18.04% | +7.80% | 122B | |
| -0.87% | +1.79% | +59.12% | +104.26% | 9.13B | |
| +1.67% | +17.63% | -42.45% | -67.15% | 4.55B | |
| +0.98% | -0.66% | +6.39% | +47.37% | 2.72B | |
| +3.55% | +4.34% | -9.81% | -18.33% | 1.66B | |
| +0.80% | -1.63% | -22.01% | -31.58% | 1.63B | |
| -0.85% | +2.25% | +2.09% | -59.02% | 1.54B | |
| +5.28% | +3.72% | -58.00% | -83.26% | 1.53B | |
| Average | +1.00% | +1.89% | -9.24% | -11.84% | 17.55B | |
| Weighted average by Cap. | -0.18% | -2.32% | -12.58% | +8.50% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SN. Stock
- Company Smith & Nephew Plc
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition